Echosens Sponsors First Annual Liver Health Matters Month in June, Celebrates 20 Years of Fighting Liver Disease Epidemic and Preventing Disease Progression
PARIS & WALTHAM, Mass.–(BUSINESS WIRE)–As part of its 20and anniversary, Echosens, a high-tech company offering FibroScan® family of products, is pleased to announce its sponsorship of the first annual Liver Health Month, an awareness initiative in June to increase awareness of the risks of chronic liver disease, including non-alcoholic fatty liver disease (NAFLD), a condition in which fat builds up in the liver, its most serious form is non-alcoholic steatohepatitis (NASH), alcohol-related hepatitis and liver disease.
Estimates show that 27 million people worldwide will have NASH, an asymptomatic, progressive and rapidly developing liver disease that can lead to increased liver-related mortality and morbidity, by 2030. FibroScan, a FDA-cleared test for diagnosing and monitoring patients as part of an overall assessment of liver health, directly and noninvasively measures the physical properties of liver stiffness and fat.
Download Echosens’ Liver Health Matters Toolkit here.
“This important awareness campaign will make more people understand the link between liver disease and obesity, type 2 diabetes, abnormal blood fat levels and metabolic syndrome,” says Dominique Legros, CEO of the Echosens group. “As sponsors, we want to both celebrate the progress we have already made with wider use of FibroScan and galvanize the fight to help reverse the progression of liver disease. “Early assessment and monitoring of liver fat and stiffness has never been more critical.”
He adds that a growing number of self-insured employers and plan sponsors are faced with the alarming statistics on the prevalence of NAFLD and NASH, which is associated with a 3-fold increase in all-cause mortality in this population, attributable to the addition of liver diseases. associated mortality.
Jon Gingrich, CEO of Echosens North America, said, “Liver Health Matters Month will educate the public and professionals about the critical value of early detection and monitoring of fatty liver disease through traditional and digital media, social media and community outreach.
A pioneer in its field, Echosens has considerably changed the practice of liver function tests with FibroScan®, the non-invasive solution for comprehensive liver health management. FibroScan® is recognized worldwide and validated by more than 2,500 peer-reviewed publications and 70 international guidelines. Echosens created the FibroScan® available in over 100 countries enabling millions of liver examinations worldwide. https://www.echosens.com/